Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Covid Vaccin Allo
NCT04951323Phase 3Unknown
- Sponsor
- University of Liège
- Start
- Mar 2021
- Primary completion
- Dec 2022
- Modality
- Vaccines & Immunotherapeutics, Lipid-based Nanoparticles, mRNA Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of tozinameran in coronavirus disease 2019 (COVID-19), sponsored by University of Liège. Status: unknown.
02
Drugs
tozinameran
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04951323.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04951323.